New diabetes pill shows promise in early safety trial
NCT ID NCT04426474
First seen May 27, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This early-stage study tested an oral drug called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check safety and side effects, while also measuring how the drug moves through the body and affects blood sugar. Participants took the drug or a placebo for up to 18 weeks, with frequent visits and blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami
Hialeah, Florida, 33014, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78229, United States
-
Hassman Research Institute
Marlton, New Jersey, 08053, United States
-
Midwest Clinical Research Unit
Dayton, Ohio, 45417, United States
-
Profil Institut für Stoffwechselforschung
Neuss, North Rhine-Westphalia, 41460, Germany
-
Profil Mainz
Mainz, 55116, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3502970 (oral drug)
What this could lead to
If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to improve blood sugar in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.